Humanized bispecific antibody against HER3 and Gal-3BP
- Humanized bispecific antibody against HER3 and Gal-3BP.
- Preclinical proof of efficacy established: inhibition of HER3 activation/downstream signaling in various tumor cell lines and inhibition of capillary-like structures in HUVEC
- Indications in Oncology: cancers whose growth and progression depend on HER3 and Gal-3BP-promoted angiogenesis, including but not limited to those arising from breast, prostrate, ovary, lung, pancreas, stomach and melanoma.
